GTP
NTLA icon

Global Thematic Partners’s Intellia Therapeutics NTLA Stock Holding History

Global Thematic Partners’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-502,327
Closed -$12.5M – 60
2017
Q3 		$12.5M Buy
+502,327
New +$9.46M 0.4% 54

Other funds holding NTLA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Global Thematic Partners's NTLA Position: Q4 2017 in Review

Global Thematic Partners sold out of Intellia Therapeutics (NTLA) in Q4 2017, closing a stake of 502,327 shares — an estimated $12.5M sold.

Global Thematic Partners first reported a position in NTLA in Q3 2017 and held it in 1 quarter. The position peaked at $12.5M in Q3 2017. 112 funds tracked by Wall St. Rank hold NTLA as of Q4 2017.

  • Global Thematic Partners reported no remaining Intellia Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Global Thematic Partners sold 502,327 Intellia Therapeutics shares in Q4 2017, an estimated $12.5M.
  • Global Thematic Partners first reported a position in Intellia Therapeutics in Q3 2017 and held it in 1 quarter.
  • Global Thematic Partners's Intellia Therapeutics position peaked at $12.5M in Q3 2017.
  • 112 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2017.

Based on Global Thematic Partners's 13F filing for Q4 2017, filed 29 Jan 2018.